ABSTRACT
OBJECTIVE: To detect changes of serum soluble Apo-1/Fas (sApo-1/Fas) in pancreatic cancer patients and to investigate its clinical value in assessing the effect of chemotherapy. METHODS: The serum level of sApo-1/Fas in 30 normal control subjects and 58 pancreatic cancer patients were detected using enzyme-linked immunosorbent assay (ELISA), and the sApo-1/Fas level of 48 pancreatic cancer patients, before and after chemotherapy was compared. RESULTS: Compared with the level of the control group, the level of serum soluble Apo-1/Fas was significantly correlated with clinical stage but not with age, sex or pathologic type of pancreatic cancer. It was elevated gradually from stage II to IV (P < 0.01). However, it would obviously decrease in pancreatic cancer patients after chemotherapy (P < 0.01). CONCLUSION: The serum soluble Apo-1/Fas may be involved in the development of pancreatic cancer, and it may be used as one parameter to assess the disease status and prognosis of pancreatic cancer patient.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Pancreatic Neoplasms/blood , fas Receptor/blood , Adenocarcinoma, Mucinous/blood , Adenocarcinoma, Mucinous/drug therapy , Adult , Carcinoma, Pancreatic Ductal/blood , Carcinoma, Pancreatic Ductal/drug therapy , Cisplatin/administration & dosage , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Disease Progression , Female , Humans , Male , Middle Aged , Neoplasm Staging , Pancreatic Neoplasms/drug therapy , Prognosis , Remission Induction , GemcitabineABSTRACT
BACKGROUND & OBJECTIVE: Literatures reported that the soluble Apo-1/Fas(sApo-1/Fas) levels in serum of patients with malignant carcinoma were higher than that in normal control subject, but there were fewer studies was seldom to detect the level of sApo-1/Fas in patients with malignancy carcinoma and effect of chemotherapy; the subject is to detect the level of sApo-1/Fas in patients with gastric carcinoma and effect of chemotherapy on it, and to investigate its clinical value. METHODS: Enzyme linked immunosorbent assays(ELISA) was available to detect the level of sApo-1/Fas in 42 case of patients with gastric carcinoma before and after chemotherapy, as compared with 30 case of normal control subject. RESULTS: Levels of sApo-1/Fas were elevated in all subgroups of patients with gastric carcinoma as compared to the controls (P < 0.01), sApo-1/Fas was correlated with clinical stage and histological grade, and not with sex, age; the sApo-1/Fas level in stage IV was higher in comparison with stage III and II (P < 0.05-0.01), and in stage III it was higher than in stage II (P < 0.05); being lower in the well differentiated and moderately differentiated than the poorly differentiated(P < 0.05-0.01), that the sApo-1/Fas levels were remarkably reduced in complete remission or partial remission patients(P < 0.01) after chemotherapy. CONCLUSION: sApo-1/Fas may play closely reflect growth and regulation in gastric carcinoma, it may be a predictor for biological behaviors and prognosis of gastric carcinoma; sApo-1/Fas may be a new target in treating gastric carcinoma.
